During the Association for Accessible Medicines’ Access! 2019 meeting, Doug Long, vice president of industry relations at IQVIA, gave an update about what trends are being identified in the generic and biosimilars markets across the globe.
During the Association for Accessible Medicines’ Access! 2019 meeting, Doug Long, vice president of industry relations at IQVIA, gave an update about what trends are being identified in the generic and biosimilars markets across the globe.
According to data collected by IQVIA, FDA abbreviated New Drug Applications (ANDA) are being approved at twice the typical rate for the fourth year in a row. According to Long, however, the ANDA backlog is estimated to be around 50% of peak level (nearly 4000) and getting that number down to zero is somewhat unlikely.
Interestingly, though the FDA has been approving ANDAs at an accelerated rate since 2014, the number of ANDA withdrawals has also increased. In 2018, the FDA approved a record number of 735 ANDAs, and the agency also saw a record 71 withdrawals. Furthermore, many ANDA products, once approved, are not being launched. Of the 735 that were approved in 2018, as of December 2018, only 261 had launched.
Long explained that in 2017, spending on medicines in the United States grew 0.6%, notably slower than in years past. Additionally, Long stated that in 2017, there was a 44% difference in the average wholesale acquisition cost (WAC) to net discount for branded protects and a 64% difference for generics. “The most meaningless data point that I’ve ever come across is list pharmaceutical prices,” said Long.
He then moved on to discuss the trends seen in the biosimilar market, both locally and abroad. Long presented data that showed the United States to be among the slowest developed countries to commercialize when the first biosimilar of a molecule becomes available.
“For example, biosimilar [adalimumab] (Humira) launched in Europe in October 2018. We’re not expecting that here [in the United States] until 2023, unless Boehringer Ingelheim figures out their litigation” against the reference product developer, AbbVie.
In terms of market share, Long broke down the data by product per molecule as of January 2019:
Filgrastim:
Infliximab:
Pegfilgrastim:
Long believes that the lack of biosimilar uptake in the United States “is not a regulatory problem, it’s commercial.” In countries where hospitals or providers are required to prescribe their patient the lowest-cost available option, such as Denmark, biosimilar penetration (as of October 2018) was extremely high. For biosimilar infliximab alone, Denmark reported figures of 98.5% market penetration.
However, the biosimilar market in the United States still holds great potential, he said. From 2019 to 2023, the impact of brand loss of exclusivity is estimated to be worth nearly $95 billion, opening up the market for new biosimilar entry.
Long quoted an industry consultant he questioned about what he sees lies in store for the biosimilar market. He said, “As more and more products come to market, and the products are in wider distribution and there are no identified problems, then perhaps the uptake in the market may improve.”
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
May 6th 2025Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access
April 28th 2025Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Oncology Biosimilars Cut Costs; Diabetes and Other Diseases Could Follow
May 6th 2025Shreehas P. Tambe, MD, highlighted the significant potential for biosimilars to expand into other disease areas like diabetes, offering crucial cost-saving solutions amid a rising global burden of noncommunicable diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
FDA's Expanded Access: From Laetrile to Right to Try, Ethical Debates Over Early Drug Access
April 28th 2025Christopher T. Robertson, JD, PhD, reviewed the history and ethical landscape of providing access to drugs before FDA approval, highlighting the crucial role of clinical trials and ethical safeguards at the 2025 Festival of Biologics USA.
2 Commerce Drive
Cranbury, NJ 08512